- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05002647
Relationship Between the Clinical Pharmacist & Antibiotic Use by Using the Electronic Program
August 13, 2021 updated by: Alexandria University
Relationship Between the Clinical Pharmacist & Antibiotic Use in Selected Infectious Disease Hospitals in El Beheira by Using the Electronic Program, Retrospective Cohort
A retrospective cohort study to explore the association between clinical pharmacists' interventions and antibiotic consumption through the use of the medical electronic reports and to identify mortality and cost savings in hospital infectious disease.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
The role of clinical pharmacist includes :
- a check of suitable selection and dosing of antimicrobials according to the diagnosis, type of infection, antimicrobial cultures as possible, comorbidities of patients (renal or hepatic function, etc), adverse effect, and drug interaction with other drugs.
- Documentation of the clinical intervention, cost-saving, adverse effect,, antimicrobial culture and antimicrobial consumption on the electronic program (CPC "clinical patient care").
- The clinical pharmacist inspector reviews the data recorded on CPC.
Study Type
Observational
Enrollment (Anticipated)
3000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Maged El-Setouhy
- Email: ma.elsetouhy@gmail.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
All patients who administered antimicrobials
Description
Inclusion Criteria:
- All inpatient with infectious disease (disorders caused by organisms as (bacteria, viruses, fungi, or parasites).
Exclusion Criteria:
- Any other cause of hospital admission other than infectious disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
exposure group
Data from electronic clinical pharmacist records of two infectious disease hospitals
|
There is no intervention
|
Non-exposure group A
Data from medical records of the hospital with no clinical pharmacy.
|
There is no intervention
|
Non-exposure group B
Data from a medical record of the hospital with clinical pharmacy, but the department did not cover by the clinical pharmacy
|
There is no intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antimicrobial consumption
Time Frame: 2 years
|
consumption of antimicrobials (defined daily doses / 100 patient-days)
|
2 years
|
Days of therapy (DOT)
Time Frame: 2 years
|
Number of days of each antimicrobial received for therapy
|
2 years
|
Length of therapy(LOT)
Time Frame: 2 years
|
The number of days a patient takes an antibacterial drug, regardless of the number of different medications
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cost savings
Time Frame: 2 years
|
(initial treatment cost × days before intervention) - (cost after intervention × days with this treatment),
|
2 years
|
Mortality rate
Time Frame: 2 years
|
in-hospital mortality rate (%)
|
2 years
|
Antimicrobial resistance
Time Frame: 2 years
|
resistance defined as resistance to at least one antimicrobial from the panel for all organisms, and for a subset of organisms belonging to the ESKAPE group (Enterococcus faecium, S. aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa , and Enterobacter spp.
|
2 years
|
The incidence of adverse reaction of antimicrobial
Time Frame: 2 years
|
An unexpected medical problem that happens during treatment with antimicrobial.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Amira zidane, Ministry of Health and Population, Egypt
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Karakonstantis S, Kalemaki D. Antimicrobial overuse and misuse in the community in Greece and link to antimicrobial resistance using methicillin-resistant S. aureus as an example. J Infect Public Health. 2019 Jul-Aug;12(4):460-464. doi: 10.1016/j.jiph.2019.03.017. Epub 2019 Apr 10.
- Dyar OJ, Huttner B, Schouten J, Pulcini C; ESGAP (ESCMID Study Group for Antimicrobial stewardshiP). What is antimicrobial stewardship? Clin Microbiol Infect. 2017 Nov;23(11):793-798. doi: 10.1016/j.cmi.2017.08.026. Epub 2017 Sep 4.
- Ourghanlian C, Lapidus N, Antignac M, Fernandez C, Dumartin C, Hindlet P. Pharmacists' role in antimicrobial stewardship and relationship with antibiotic consumption in hospitals: An observational multicentre study. J Glob Antimicrob Resist. 2020 Mar;20:131-134. doi: 10.1016/j.jgar.2019.07.009. Epub 2019 Jul 16.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
August 15, 2021
Primary Completion (Anticipated)
February 1, 2022
Study Completion (Anticipated)
July 1, 2022
Study Registration Dates
First Submitted
August 7, 2021
First Submitted That Met QC Criteria
August 7, 2021
First Posted (Actual)
August 12, 2021
Study Record Updates
Last Update Posted (Actual)
August 19, 2021
Last Update Submitted That Met QC Criteria
August 13, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- 14-2021/13
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clinical Pharmacists
-
Rabin Medical CenterCompletedHip Fractures | Rehabilitation Outcome | Clinical PharmacistsIsrael
-
University of WaterlooCompletedMedication Therapy Management | Home Care | PharmacistsCanada
-
Prof. Dr. med. Cornelius BollheimerCompletedPharmacists in Geriatric Health Services | Conditions UnspecifiedGermany
-
Cairo UniversityNot yet recruiting
-
Hawler Medical UniversityCompletedClinical Performance | Objective Structured Clinical ExaminationIraq
-
The University of Texas Health Science Center,...CompletedUnderstanding of Consent in Clinical Research | Implementation of Consent in Clinical ResearchUnited States
-
University Vila VelhaNot yet recruiting
-
Cairo UniversityRecruiting
-
Guangzhou Lupeng Pharmaceutical Company LTD.Completed
-
BayerJanssen Research & Development, LLCCompleted
Clinical Trials on NO intervention
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
Case Western Reserve UniversityAmerican UniversityNot yet recruitingNutrition, Healthy
-
University of Dublin, Trinity CollegeCompleted
-
Hôpital Necker-Enfants MaladesUnknown
-
China Medical University HospitalUnknownIntention to Stay, Turnover Behavior